Molsid

New generation of fluorogenic molcular probes for applications in Health & other industries

  • Stage Product In Market
  • Industry Biotechnology
  • Location Lyon, France
  • Currency EUR
  • Founded August 2018
  • Employees 10
  • Incorporation Type Other
  • Website molsid.com

Company Summary

AMR is a growing public health issue. WHO declares >10M deaths p/y due to AMR by 2050. Today, clinicians cannot clearly detect AMR in emergency. Available tests give results in 12-48hrs, leading to problems: patients are not isolated and spread bacteria and they receive wrong treatments. This raises AMR incidence and prolongs costly hospitalization. Our game-changing kit is easy to use and cost-efficient. In less than 2hrs it can save lives.

Team

  • Chairman

    20y of experience in innovation management, business set-up and strategy, team and project management, international marketing, MA Project Management

  • 25y of experience in finance, control and HR administration in various biotech and medtech companies, MSc Biology & MA Corporate finance

  • Jens Hasserodt
    Co-founder and Scientific advisor

    25y of experience in organic chemistry, 10 patents filed, 16 publications, Professor and researcher at ENS Lyon, PhD chemistry

Advisors

Previous Investors

  • Bernard Mandrand, PhD, Président Mandrand S.A.S., ex Dir Scientifique bioMérieux et Lyonbiopôle
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free